MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.39
-0.52
-2.75%
After Hours: 18.50 +0.11 +0.60% 19:57 11/23 EST
OPEN
18.98
PREV CLOSE
18.91
HIGH
18.98
LOW
18.18
VOLUME
3.09M
TURNOVER
--
52 WEEK HIGH
27.80
52 WEEK LOW
13.67
MARKET CAP
5.68B
P/E (TTM)
38.42
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Strong Sell Stocks for November 11th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Zacks · 11/11 13:24
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Zacks · 11/06 15:33
Exelixis (EXEL) Reports Q3 Loss, Tops Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/06 01:30
Exelixis Q3 EPS $0.04 Beats $0.01 Estimate, Sales $231.10M Beat $215.49M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 88.24 percent decrease over earnings of $0.34 per share from the same
Benzinga · 11/05 22:05
Exelixis EPS beats by $0.03, beats on revenue
Exelixis (EXEL): Q3 Non-GAAP EPS of $0.04 beats by $0.03; GAAP EPS of -$0.10 misses by $0.11.Revenue of $231.09M (-14.9% Y/Y) beats by $15.69M.“In the third quarter of 2020, the
Seekingalpha · 11/05 21:09
Exelixis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Exelixis, Inc.
ACCESSWIRE · 11/05 20:45
Exelixis Q3 Earnings Preview
Exelixis (NASDAQ:EXEL) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is $0.01 (-97.1% Y/Y) and the consensus Revenue Estimate is $215.4M
Seekingalpha · 11/04 22:35
Were These Hedge Funds Wrong About Exelixis, Inc. (EXEL)?
Is Exelixis, Inc. (NASDAQ:EXEL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
Insider Monkey · 11/03 17:46
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXEL stock price target is 30.85 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 553
Institutional Holdings: 270.76M
% Owned: 87.62%
Shares Outstanding: 309.00M
TypeInstitutionsShares
Increased
105
15.33M
New
92
2.48M
Decreased
141
15.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Co-Founder/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Corporate Executive
Gisela Schwab
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel
Jeffrey Hessekiel
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jack Wyszomierski
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.